Home > Pipeline > KPI-190

KPI-190 is another member of our Kv1.3 inhibitor platform being developed as an eye drop for use in several eye diseases including uveitis and autoimmune Dry Eye Syndrome (aDES).

Pathogenic T cells have been shown to play a role in autoimmune eye disease as T cell infiltration and cytokine and chemokine production lead to tissue damage in the eye. Kv1.3-high autoreactive TEM cells have been identified in uveitis and DES making these conditions a good option for development of KPI-190.

Therapeutic Need – Uveitis

Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with very few treatment options. Dry eye syndrome affects over 13 million people a year in the US alone and current treatments are either ineffective at treating the underlying disease or are toxic if used over long periods of time.

Development Status

KPI-190 has demonstrated proof of concept efficacy in models of anterior uveitis, and when topically administered demonstrates good penetration into the anterior chamber.

Publications and Presentations